Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.20 USD
+0.01 (0.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.19 -0.01 (-0.83%) 6:14 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Average Brokerage Rating
Current ABR | 2.78 |
ABR (Last week) | 2.78 |
# of Recs in ABR | 9 |
Average Target Price | $1.80 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.28 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 8 | 8 | 8 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.78 | 2.78 | 2.78 | 2.78 | 2.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
1/22/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Hold |
1/19/2024 | BTIG | Julian Harrison | Hold | Hold |
1/12/2024 | Cantor Fitzgerald & Co | Louise Chen | Not Available | Hold |
11/13/2023 | Piper Sandler | Christopher Raymond | Strong Buy | Hold |
11/13/2023 | William Blair | Timothy F Lugo | Strong Buy | Hold |
11/13/2023 | SVB Securities | Thomas J Smith | Strong Buy | Hold |
10/3/2023 | Evercore Partners | Gavin Clark-Gartner | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.